Diabetes: hyperglycaemia found (confirm, classify, spot the emergency)
BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.
Osmotic symptoms (thirst, polyuria, weight loss), ketosis or child: emergency
In the practice, straight away
- Urine dipstick (glucose, ketones) and capillary blood glucose
- Child or adolescent with suspected diabetes: refer the same day to a paediatric diabetes team, without waiting for laboratory tests.
- Adult with ketosis, vomiting, abdominal pain, rapid breathing or altered consciousness: emergency department (possible ketoacidosis).
Do not order
- C-peptide and diabetes autoantibodies in a child at diagnosis to distinguish type 1 from type 2: not to be done straight away [3].
Raised blood glucose without symptoms: confirm diabetes or prediabetes
Fasting laboratory tests (overnight fast of 10 to 12 hours; at least 8 hours without calorie intake)
- Confirmatory fasting venous plasma glucose
- HbA1c (second test, on the same sample or later)if neededTo confirm with a different test: two different abnormal tests (fasting plasma glucose and HbA1c), on the same day or on two dates, confirm the diagnosis [2]. Not reimbursed at diagnosis [11].
- Oral glucose tolerance test (75 g glucose, fasting and 2-hour plasma glucose)if needednon-French guidelineBorderline fasting plasma glucose and strong clinical suspicion, or HbA1c abnormality (haemoglobinopathy, pregnancy, altered red cell turnover): OGTT is a diagnostic criterion; ensure at least 150 g of carbohydrate a day during the previous 3 days [2].
Do not order
- HbA1c for screening or to make the diagnosis: neither recommended nor reimbursed in France for this indication [6,10]; the NABM limits its coverage to monitoring of glycaemic control (write “NR” (not reimbursable in France) if it is requested) [11].
- Fructosamine to screen for or diagnose diabetes: the NABM reserves it for treatment monitoring [11].
Confirmed diabetes: classify and do the initial work-up
Fasting laboratory tests
- HbA1c (baseline value to set the target)
- FBC (including platelets, for the FIB-4 score)
- Lipid profile
- Liver function tests: AST
- ALT
- GGT
- Alkaline phosphatase
- PT (to calculate the FIB-4 score)
- Serum creatinine with eGFR
- Anti-GAD antibodies (if features of type 1 diabetes)if needednon-French guidelineAdult with features of type 1 diabetes: age at diagnosis < 35 years, BMI < 25 kg/m², involuntary weight loss, ketosis, plasma glucose > 3.6 g/L (20 mmol/L) at diagnosis, rapid need for insulin [2]; to be measured early, when the false-negative rate is lowest [5].
- Anti-IA2 antibodies (if anti-GAD negative and persistent doubt)if needednon-French guidelineNegative anti-GAD while type 1 diabetes is still suspected: anti-IA2 (or anti-ZnT8) are the second step [2]; two different antibodies reduce false negatives [5].
- C-peptide with simultaneous plasma glucose (patient already on insulin, uncertain classification)if needednon-French guidelineOnly in a patient treated with insulin whose type remains uncertain, preferably at a distance from diagnosis: a non-fasting sample within 5 hours of a meal is enough [2,5].
Urine tests
- Urine albumin:creatinine ratio (spot sample)
Also consider
- Familial haemochromatosis? A family history of haemochromatosis calls for the page "Haemochromatosis".
Do not order
- C-peptide in a patient not treated with insulin to classify diabetes: it is indicated only on insulin [2].
Sources (18)
- Assurance maladie. Cartographie des pathologies et des dépenses, effectifs 2024 (data.ameli.fr, jeu « effectifs »), consulté le 24/10/2026.
- American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S27-S49.
- National Institute for Health and Care Excellence. Diabetes (type 1 and type 2) in children and young people: diagnosis and management. NICE guideline NG18 (recommandations 1.1.1 à 1.1.9).
- Libman I, Haynes A, Lyons S, Pradeep P, Rwagasor E, Tung JY, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Definition, epidemiology, and classification of diabetes in children and adolescents. Pediatr Diabetes. 2022;23(8):1160-1174.
- National Institute for Health and Care Excellence. Type 1 diabetes in adults: diagnosis and management. NICE guideline NG17 (recommandations 1.1.1 à 1.1.8).
- Haute Autorité de santé. Parcours de soins du patient adulte vivant avec un diabète de type 2. Guide, validé par le Collège le 26 juin 2025.
- Haute Autorité de santé. Stratégie thérapeutique du patient vivant avec un diabète de type 2. Recommandation de bonne pratique, validée par le Collège le 30 mai 2024.
- Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Typ-2-Diabetes, Langfassung, Version 3.0, 2023.
- Royal Australian College of General Practitioners, Diabetes Australia. Management of type 2 diabetes: a handbook for general practice. Novembre 2024, mis à jour en août 2025 : chapitres « Defining and diagnosing type 2 diabetes » et « Assessment of the person with type 2 diabetes ».
- Haute Autorité de santé. Guide parcours de soins : diabète de type 2 de l'adulte. Guide complet, mars 2014.
- Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 : actes 1577 (HbA1c), 1576 (protéines glyquées), 0412 et 0413 (hyperglycémie provoquée).
- Haute Autorité de santé. Guide parcours de soins : diabète de type 2 de l'adulte. Synthèse, mars 2014.
- US Preventive Services Task Force. Prediabetes and Type 2 Diabetes: Screening. Final Recommendation Statement, 24 août 2021 (grade B).
- National Institute for Health and Care Excellence. Type 2 diabetes: prevention in people at high risk. Public health guideline PH38, 2012, mise à jour en 2017 (paragraphe sur l'HbA1c daté de 2026).
- American Diabetes Association Professional Practice Committee. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S61-S88.
- National Institute for Health and Care Excellence. Metabolic dysfunction-associated steatotic liver disease (MASLD): assessment and management. NICE guideline NG49, 2016, mise à jour le 31 juillet 2026.
- Agence européenne des médicaments. Piqray (alpélisib) : résumé des caractéristiques du produit, rubrique 4.8.
- Agence européenne des médicaments. Afinitor (évérolimus) : résumé des caractéristiques du produit, rubrique 4.8.